LAG3 and neoplasm: Among ICs, programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1) and lymphocyte activation gene-3 (LAG-3) are attractive targets in immunotherapy, as they play an important role in various malignancies where they can attenuate the host immune response to tumor cells.